U.S. Markets
Merck (MRK) says Keytrdua lung is not the number one revenue generator anymore, future revenue increasingly expects from Adjuvant settings
Related stocks
1 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
